Novartis prostate cancer drug trial meets primary endpoint

The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.